Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Mar;73(5):560-4.
doi: 10.1038/bjc.1996.98.

Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumours

Affiliations
Free PMC article

Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumours

J D Alder et al. Br J Cancer. 1996 Mar.
Free PMC article

Abstract

Two 9-dihydrotaxane analogues were synthesised and tested for in vitro potency and in vivo efficacy against murine and human tumour xenografts in mice. The in vitro potency of 9-dihydrotaxol (9-DH-t) and 10-deacetyl-9-dihydrotaxol (10-DeAc-9-DH-t) was generally less than that of paclitaxel against human and murine tumour cells. However, both analogues were at least 20-fold more soluble than paclitaxel in water. The analogues yielded cure rates > or = 60% against human MX-1 solid tumour xenografts in mice, compared with a cure rate of 10% for mice treated with paclitaxel. Both of the analogues were more effective than paclitaxel for treatment of murine M109 solid tumour in mice. 10-DeAc-9-DH-t was as effective as paclitaxel against murine B16 ascites tumour, while 9-DH-t was less effective. Both 10-DeAc-9-DH-t and 9-DH-t were demonstrably less toxic than paclitaxel. At equal dosages 9-DH-t produced serum concentrations greater than paclitaxel, while 10-DeAc-9-DH-t yielded serum concentrations less than paclitaxel. However, the decrease in toxicity of 9-DH-t and 10-DeAc-9-DH-t allowed a 4-fold increase in daily dosage. These two 9-dihydrotaxane analogues yielded favourable preclinical data and demonstrated good potential for further development.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5 - PubMed
    1. Cancer Treat Rep. 1981 Mar-Apr;65(3-4):299-312 - PubMed
    1. Cancer Res. 1989 Aug 15;49(16):4640-7 - PubMed
    1. Ann Intern Med. 1989 Aug 15;111(4):273-9 - PubMed
    1. J Natl Cancer Inst. 1991 Feb 20;83(4):288-91 - PubMed